Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Joon Y. Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3847-9198; OpenAlex author ID A5086695712. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 6

  1. Inhibition of AXL dependent non-professional efferocytosis sensitizes pancreatic cancer to immune checkpoint blockade Co-author DOI 10.1101/2025.08.12.669943↗
  2. Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resec… First author DOI 10.1002/jso.27674↗
  3. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  4. MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling. Co-author DOI 10.1158/1078-0432.ccr-22-3322↗
  5. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  6. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Co-author DOI 10.1002/jso.26279↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy R. Donahue · 6 shared papers, 2021–2025 · strength 1.07
  2. Mark D. Girgis MD · 5 shared papers, 2021–2025 · strength 0.92
  3. Michael A. Mederos · 3 shared papers, 2021–2024 · strength 0.47
  4. Zev A. Wainberg · 3 shared papers, 2021–2024 · strength 0.41
  5. Jonathan C. King · 2 shared papers, 2021–2024 · strength 0.36
  6. Jason M. Link · 2 shared papers, 2023–2024 · strength 0.31
  7. Carlos F. Fernandez-del Castillo · 2 shared papers, 2022–2024 · strength 0.28
  8. Shimpei Maeda · 2 shared papers, 2022–2024 · strength 0.28
  9. William R. Burns · 2 shared papers, 2022–2024 · strength 0.28
  10. Jun Yu · 2 shared papers, 2022–2024 · strength 0.28
  11. Cristina Rosa Ferrone · 2 shared papers, 2022–2024 · strength 0.28
  12. Keith D. Lillemoe · 2 shared papers, 2022–2024 · strength 0.28
  13. Hoang Dao · 1 shared paper, 2025 · strength 0.28
  14. Erina Vlashi · 1 shared paper, 2025 · strength 0.28
  15. Oscar Joe Hines · 2 shared papers, 2021–2022 · strength 0.25
  16. Dustin L. Dillon · 1 shared paper, 2024 · strength 0.23
  17. Takayuki Shimizu · 1 shared paper, 2024 · strength 0.17
  18. Nikhil L. Chervu · 1 shared paper, 2024 · strength 0.17
  19. Christopher Lee Wolfgang · 1 shared paper, 2024 · strength 0.17
  20. Keke Liang · 1 shared paper, 2023 · strength 0.15
  21. Evan R. Abt · 1 shared paper, 2023 · strength 0.15
  22. Razmik Ghukasyan · 1 shared paper, 2023 · strength 0.15
  23. Caius Gabriel Radu · 1 shared paper, 2023 · strength 0.15
  24. Howard A. Reber · 1 shared paper, 2021 · strength 0.13
  25. Hanlin L. Wang · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.